Which statement about niacin's role in lipid disorders is true?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Niacin’s role in lipid disorders has become limited by evidence and safety concerns. It can meaningfully raise HDL cholesterol and lower triglycerides, and it can modestly reduce LDL, but these lipid changes don’t reliably translate into better cardiovascular outcomes when added to statin therapy. Large trials showed no extra benefit and revealed notable side effects such as flushing, glucose intolerance, and potential liver toxicity. Because of this, niacin is no longer considered a routine primary or secondary agent for dyslipidemias in most guidelines. It doesn’t replace statins as first-line therapy, since statins provide the strongest and most consistent LDL lowering and outcome benefit. Niacin is also not universally contraindicated in all lipid disorders, but its use is now limited to select situations and requires careful consideration of risks versus benefits.